[Giant-cell tumor of bone in 2022].
La tumeur à cellules géantes des os en 2022.
Bone tumor
Denosumab
Differential diagnosis
Giant cell tumor of bone
Giant cell-rich lesions
Malignant giant cell tumor of bone
Pathology
Journal
Annales de pathologie
ISSN: 0242-6498
Titre abrégé: Ann Pathol
Pays: France
ID NLM: 8106337
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
03
03
2022
accepted:
09
03
2022
pubmed:
7
5
2022
medline:
9
6
2022
entrez:
6
5
2022
Statut:
ppublish
Résumé
Giant cell tumors of bone (GCTs) are rare mesenchymal tumors classified as intermediate in the WHO 2020 classification, i.e. neither completely benign nor definitely malignant, due to recurrence (frequent) and pulmonary metastases (rare). They involve the end of long bones as well as the axial bones of mature skeletons. They are made of mononuclear stromal tumor cells of (pre-) osteoblastic phenotype, mononuclear cells of the monocyte-macrophage lineage and osteoclast-like multinuclear giant cells responsible for tumor osteolysis. In 95% of cases, the stromal cells have a specific mutation in the H3F3A gene which encodes histone H3.3. The mutated H3.3 G34W protein (90% of cases) can be easily detected by immunohistochemistry, even on small samples. Many tumors or bone pseudotumors contain osteoclast-like giant cells, cells of the bone microenvironment, and should not be confused with GCT: mainly brown tumor of hyperparathyroidism, aneurysmal bone cyst, chondroblastoma, non-ossifying fibroma and central giant cell granuloma.
Identifiants
pubmed: 35523609
pii: S0242-6498(22)00063-3
doi: 10.1016/j.annpat.2022.03.004
pii:
doi:
Substances chimiques
Histones
0
Types de publication
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
214-226Informations de copyright
Copyright © 2022 Elsevier Masson SAS. All rights reserved.